Suppr超能文献

6692 例患者中 0.5%PVP-I 漱口液和滴鼻剂的耐受性和可用性:观察性研究。

Tolerability and usability of 0.5% PVP-I gargles and nasal drops in 6692 patients: Observational study.

机构信息

Consultant Sushrut ENT Hospital and Dr. Khan's ENT Research Center, Talegaon Dabhade, India.

出版信息

Am J Otolaryngol. 2021 Mar-Apr;42(2):102880. doi: 10.1016/j.amjoto.2020.102880. Epub 2021 Jan 4.

Abstract

OBJECTIVES

STUDY DESIGN: Observational study.

SETTING

Secondary care ENT Centre.

METHODS

All patients attending the hospital for office ENT consultations from 15th April 2020 to 15th September 2020 were included in the study. A total of 6692 office patients were evaluated for feasibility, usability and tolerability of the 0.5% PVP-I gargles and nasal drops.

RESULTS

Overall practicability of using 0.5% PVP-I gargles and nasal drops at office level was assessed in terms of feasibility and usability. Feasibility and usability was considered in terms of the ease of the dispensing method of the 0.5% PVP-I gargles and nasal drops by the health care workers to the patients prior to ENT examination. Tolerance was assessed in terms of altered taste, staining of teeth or nasal skin or irritation in the nose. None reported any serious reactions or adverse effects following use of 0.5% PVP-I.

CONCLUSION

The study reports the successful feasibility and usability of 0.5% PVP-I gargles and nasal drops and bears the potential to provide benefits in preventing transmission from the patients to the health care workers and vice versa.

LEVEL OF EVIDENCE

摘要

目的

研究设计:观察性研究。

地点

二级保健耳鼻喉中心。

方法

从 2020 年 4 月 15 日至 2020 年 9 月 15 日,所有在医院就诊的耳鼻喉科门诊患者均纳入本研究。共有 6692 名门诊患者评估了 0.5%PVP-I 漱口液和滴鼻剂的可行性、可用性和耐受性。

结果

总体而言,在门诊环境下使用 0.5%PVP-I 漱口液和滴鼻剂的实用性是根据可行性和可用性来评估的。可行性和可用性是根据医护人员在耳鼻喉科检查前向患者分配 0.5%PVP-I 漱口液和滴鼻剂的简便程度来考虑的。耐受性是根据味觉改变、牙齿或鼻腔皮肤染色或鼻腔刺激来评估的。无人报告使用 0.5%PVP-I 后出现任何严重反应或不良反应。

结论

本研究报告了 0.5%PVP-I 漱口液和滴鼻剂的成功可行性和可用性,并具有潜在的益处,可以防止患者向医护人员传播,反之亦然。

证据水平

4 级。

相似文献

1
Tolerability and usability of 0.5% PVP-I gargles and nasal drops in 6692 patients: Observational study.
Am J Otolaryngol. 2021 Mar-Apr;42(2):102880. doi: 10.1016/j.amjoto.2020.102880. Epub 2021 Jan 4.
2
Repurposing 0.5% povidone iodine solution in otorhinolaryngology practice in Covid 19 pandemic.
Am J Otolaryngol. 2020 Sep-Oct;41(5):102618. doi: 10.1016/j.amjoto.2020.102618. Epub 2020 Jun 18.
4
In Vitro Efficacy of a Povidone-Iodine Nasal Antiseptic for Rapid Inactivation of SARS-CoV-2.
JAMA Otolaryngol Head Neck Surg. 2020 Nov 1;146(11):1054-1058. doi: 10.1001/jamaoto.2020.3053.
5
Considerations for povidone-iodine antisepsis in pediatric nasal and pharyngeal surgery during the COVID-19 pandemic.
Am J Otolaryngol. 2020 Nov-Dec;41(6):102737. doi: 10.1016/j.amjoto.2020.102737. Epub 2020 Sep 19.
6
Efficacy of Povidone-Iodine Nasal and Oral Antiseptic Preparations Against Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2).
Ear Nose Throat J. 2021 Apr;100(2_suppl):192S-196S. doi: 10.1177/0145561320957237. Epub 2020 Sep 21.
8
Preanesthetic Povidone-Iodine gargles for patients with COVID-19.
J Clin Anesth. 2020 Dec;67:110035. doi: 10.1016/j.jclinane.2020.110035. Epub 2020 Sep 10.
9
0.5% povidone iodine irrigation in otorhinolaryngology surgical practice during COVID 19 pandemic.
Am J Otolaryngol. 2020 Nov-Dec;41(6):102687. doi: 10.1016/j.amjoto.2020.102687. Epub 2020 Aug 19.
10
A case of COVID-19 infection quickly relieved after nasal instillations and gargles with povidone iodine.
Rev Cardiovasc Med. 2021 Jun 30;22(2):269-270. doi: 10.31083/j.rcm2202033.

引用本文的文献

1
Efficacy of different mouthwashes against COVID-19: A systematic review and network meta-analysis.
Jpn Dent Sci Rev. 2023 Dec;59:334-356. doi: 10.1016/j.jdsr.2023.09.003. Epub 2023 Oct 11.
2
Evaluation of Current Evidence on the Use of Oral Antiseptics Against SARS-CoV-2: A Narrative Review.
J Int Soc Prev Community Dent. 2022 Oct 31;12(5):488-499. doi: 10.4103/jispcd.JISPCD_65_22. eCollection 2022 Sep-Oct.
5
In vitro inactivation of SARS-CoV-2 using a povidone-iodine oral rinse.
BMC Oral Health. 2022 Feb 25;22(1):47. doi: 10.1186/s12903-022-02082-9.

本文引用的文献

1
0.5% povidone iodine irrigation in otorhinolaryngology surgical practice during COVID 19 pandemic.
Am J Otolaryngol. 2020 Nov-Dec;41(6):102687. doi: 10.1016/j.amjoto.2020.102687. Epub 2020 Aug 19.
2
Repurposing 0.5% povidone iodine solution in otorhinolaryngology practice in Covid 19 pandemic.
Am J Otolaryngol. 2020 Sep-Oct;41(5):102618. doi: 10.1016/j.amjoto.2020.102618. Epub 2020 Jun 18.
3
SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes.
Nat Med. 2020 May;26(5):681-687. doi: 10.1038/s41591-020-0868-6. Epub 2020 Apr 23.
4
SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients.
N Engl J Med. 2020 Mar 19;382(12):1177-1179. doi: 10.1056/NEJMc2001737. Epub 2020 Feb 19.
5
The efficacy of diluted topical povidone-iodine rinses in the management of recalcitrant chronic rhinosinusitis: a prospective cohort study.
Eur Arch Otorhinolaryngol. 2019 Dec;276(12):3373-3381. doi: 10.1007/s00405-019-05628-w. Epub 2019 Sep 27.
6
Infectious Disease Management and Control with Povidone Iodine.
Infect Dis Ther. 2019 Dec;8(4):581-593. doi: 10.1007/s40121-019-00260-x. Epub 2019 Aug 14.
7
In Vitro Bactericidal and Virucidal Efficacy of Povidone-Iodine Gargle/Mouthwash Against Respiratory and Oral Tract Pathogens.
Infect Dis Ther. 2018 Jun;7(2):249-259. doi: 10.1007/s40121-018-0200-7. Epub 2018 Apr 9.
8
Povidone-Iodine-Based Solutions for Decolonization of Nasal Staphylococcus aureus: A Randomized, Prospective, Placebo-Controlled Study.
J Arthroplasty. 2017 Sep;32(9):2815-2819. doi: 10.1016/j.arth.2017.04.039. Epub 2017 May 3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验